You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Selective D2-like dopamine receptor agonist (Ki values are 0.7, 1.5, 9.0 and 165 nM for D2, D3, D4 and D5 receptors respectively) that also displays high affinity for several serotonin receptor subtypes (Ki = 1.2 - 20.0 nM for 5-HT1A, 5-HT1D, 5-HT2A and 5-HT2B). Inhibits secretion of prolactin and growth hormone and reverses levodopa-induced dyskinesias in Parkinsonian monkeys.
|Storage||Store at +4°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 451.6. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.21 mL||11.07 mL||22.14 mL|
|5 mM||0.44 mL||2.21 mL||4.43 mL|
|10 mM||0.22 mL||1.11 mL||2.21 mL|
|50 mM||0.04 mL||0.22 mL||0.44 mL|
References are publications that support the biological activity of the product.
Eguchi et al (1995) Effect of cabergoline, a DA agonist, on estrogen-induced rat pituitary tumors:in vitro culture studies. Endocr.J. 42 413 PMID: 7670571
Kvernmo et al (2006) A review of the receptor-binding and pharmacokinetic properties of DA agonists. Clin.Ther. 28 1065 PMID: 16982285
Hadj Tahar et al (2000) Sustained caberg. treatment reverses levodopa-induced dyskinesias in parkinsonian monkeys. Cin.Neuropharmacol. 23 195
If you know of a relevant reference for Cabergoline, please let us know.
View Related Products by Product Action
Keywords: Cabergoline, Cabergoline supplier, Selective, D2-like, agonists, Dopamine, Non-Selective, Receptors, dopaminergic, Non-selective, 2664, Tocris Bioscience
4 Citations for Cabergoline
Citations are publications that use Tocris products. Selected citations for Cabergoline include:
Gao et al (2017) Expression of Stem Cell Markers and DA D2 Receptors in Human and Rat Prolactinomas. Med Sci Monit 23 1827 PMID: 28411401
Odaka et al (2014) Cabergoline, DA D2 receptor agonist, prevents neuronal cell death under oxidative stress via reducing excitotoxicity. J Biol Chem 9 e99271 PMID: 24914776
Leng et al (2017) Activation of DRD5 inhibits tumor growth by autophagic cell death. Autophagy 13 1404 PMID: 28613975
Lin et al (2015) Suppression of mTOR pathway and induction of autophagy-dependent cell death by caberg. PLoS One 6 39329 PMID: 26513171
Do you know of a great paper that uses Cabergoline from Tocris? Please let us know.
Reviews for Cabergoline
There are currently no reviews for this product. Be the first to review Cabergoline and earn rewards!
Have you used Cabergoline?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Dopamine Receptors Scientific Review
Written by Phillip Strange and revised by Kim Neve in 2013, this review summarizes the history of the dopamine receptors and provides an overview of individual receptor subtype properties, their distribution and identifies ligands which act at each receptor subtype. Compounds available from Tocris are listed.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.
Schizophrenia is a debilitating psychiatric disorder that affects 1% of the worldwide population. This poster describes the neurobiology of Schizophrenia, as well as highlighting the genetic and environmental factors that play a fundamental role in the etiology of the disease. The current and emerging drug targets are also discussed.